H.C. Wainwright Upgrades Price Target for Lexicon Pharmaceuticals to $6

H.C. Wainwright has raised its price target for Lexicon Pharmaceuticals (LXRX) to $6 from $4 while maintaining a Buy rating, reflecting a revised outlook on the biotech's near-term potential.

• H.C. Wainwright raised its price target for LXRX to $6 from $4
• The firm maintains a Buy rating on Lexicon Pharmaceuticals
• The new price target is below the current market price
• No new company-specific catalysts were cited in the update
• The revision reflects a reevaluation of LXRX’s development pipeline
• The change is part of routine analyst coverage within the healthcare sector